MX2017005807A - Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. - Google Patents

Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.

Info

Publication number
MX2017005807A
MX2017005807A MX2017005807A MX2017005807A MX2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A
Authority
MX
Mexico
Prior art keywords
treatment
peptides
brain metastasis
specific immune
immune therapy
Prior art date
Application number
MX2017005807A
Other languages
English (en)
Inventor
Costantini Dominique
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MX2017005807A publication Critical patent/MX2017005807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Abstract

La presente invención se refiere a una composición de vacuna de péptidos OSE-2101 para el tratamiento de metástasis cerebrales en pacientes positivos para HLA-A2.
MX2017005807A 2014-11-06 2014-11-06 Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. MX2017005807A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/073975 WO2016070928A1 (en) 2014-11-06 2014-11-06 Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis

Publications (1)

Publication Number Publication Date
MX2017005807A true MX2017005807A (es) 2017-08-02

Family

ID=51871025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005807A MX2017005807A (es) 2014-11-06 2014-11-06 Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.

Country Status (16)

Country Link
US (1) US10434157B2 (es)
EP (1) EP3215184B1 (es)
JP (1) JP6474893B2 (es)
KR (1) KR102043725B1 (es)
CN (1) CN107073087B (es)
AR (1) AR102555A1 (es)
AU (1) AU2014410466B2 (es)
BR (1) BR112017009358A2 (es)
CA (1) CA2963184C (es)
EA (1) EA037271B1 (es)
ES (1) ES2874006T3 (es)
IL (1) IL250576B (es)
MX (1) MX2017005807A (es)
NZ (1) NZ729514A (es)
TW (1) TWI703982B (es)
WO (1) WO2016070928A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL255722B1 (en) * 2015-06-29 2024-01-01 Ose Immunotherapeutics A method for inducing an early memory response with an anticancer vaccine of short peptides
PT3573600T (pt) * 2017-01-25 2022-05-11 Ose Immunotherapeutics Método para fabrico de uma emulsão estável para distribuição de péptidos
KR102624844B1 (ko) * 2017-11-27 2024-01-12 오제 이뮈노테라프틱스 암의 향상된 치료
CN109988748A (zh) * 2017-12-29 2019-07-09 深圳华大生命科学研究院 一种从til筛选肿瘤特异性t细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522812C (en) * 2003-04-18 2012-08-21 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
CN103145803B (zh) * 2012-12-13 2014-03-12 东南大学 一种与乳腺癌脑转移细胞特异性结合的多肽

Also Published As

Publication number Publication date
EA037271B1 (ru) 2021-03-02
US10434157B2 (en) 2019-10-08
NZ729514A (en) 2019-12-20
AU2014410466A1 (en) 2017-03-30
CN107073087A (zh) 2017-08-18
IL250576B (en) 2019-09-26
EP3215184B1 (en) 2021-03-03
JP2017533898A (ja) 2017-11-16
US20170319672A1 (en) 2017-11-09
JP6474893B2 (ja) 2019-02-27
TWI703982B (zh) 2020-09-11
AR102555A1 (es) 2017-03-08
CN107073087B (zh) 2020-09-08
WO2016070928A1 (en) 2016-05-12
KR102043725B1 (ko) 2019-11-13
BR112017009358A2 (pt) 2017-12-19
EP3215184A1 (en) 2017-09-13
EA201790990A1 (ru) 2017-09-29
TW201625287A (zh) 2016-07-16
ES2874006T3 (es) 2021-11-04
IL250576A0 (en) 2017-03-30
CA2963184C (en) 2020-11-24
AU2014410466B2 (en) 2019-09-12
CA2963184A1 (en) 2016-05-12
KR20170098811A (ko) 2017-08-30

Similar Documents

Publication Publication Date Title
IL260383B (en) Low dose medication
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
HK1225968A1 (zh) 用於治療hbv感染的組合療法
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
PT3212233T (pt) Terapia combinada para o tratamento de doenças
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MD4733B1 (ro) Anticorpi anti-TIGIT
EA201691582A1 (ru) Новые фармацевтические препараты
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
SG11201609014TA (en) Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
HK1256033A1 (zh) 用於刺激免疫系統的肽
HK1258128A1 (zh) 選擇病人接受組合療程
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
HK1231386A1 (zh) 免疫疾病的治療
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
IL289544A (en) Methods for administering anti-fibrotic therapy
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины